Hideki Furuya, PhD

Hideki Furuya, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 441-7719

Associate Member, Cancer Biology Program, University of Hawaiʻi Cancer Center

Academic Appointment(s):
Assistant Researcher (Assistant Professor), University of Hawaiʻi Cancer Center, University of Hawaiʻi at Mānoa

MS (Animal Nutrition), Meiji University, Department of Life Sciences, Japan
PhD (Animal Carcinogenesis), Meiji University, Department of Life Sciences, Japan
Postdoctoral Training (Molecular Biology), Medical University of South Carolina, Charleston

Research Focus

Identification of urine-based biomarkers for bladder cancer detection and diagnosis
Cancer of the urinary bladder is the fifth most common cancer in the United States. Most of non-muscle invasive bladder cancer (NMIBC) or early stage of muscle invasive bladder cancer (MIBC) can be cured by surgical resection, while late stage MIBC is fatal in most of cases. Unfortunately, up to 45% of NMIBC progressed to MIBC after 5 years, leading to dismal survival rates associated with more advanced disease. The recurrence phenomenon of NMIBC makes it one of the most prevalent cancers worldwide and is, therefore, a great burden to healthcare systems. Thus, the development of early detection tools is required. To date, we have identified a novel urine-based BCa associated diagnostic signature comprised of 10 targets, including PAI-1 and angiogenin. We recently investigated the expression pattern of the urine-based signature proteins in solid bladder tumor tissue. To move promising biomarker panels towards clinical utility, we have developed a multiplex ELISA system and tested its performance in an independent cohort. In addition to the 10 biomarkers, we also confirmed that CXCL1 level is increased in voided urine from bladder cancer subjects, suggesting that CXCL1 is also a potential biomarker. Currently, we are investigating the mechanism by which PAI-1, angiogenin, and CXCL1 induce bladder tumorigenesis using molecular and cellular biology techniques.

To assess the SphK1/S1P pathway as a strategy for cancer chemoprevention
The project goal is to develop a promising strategy for cancer chemoprevention without adverse side effects. We identified the novel mechanism by which sphingolipids pathways play important roles in colon, breast and head and neck cancers using cell cultures and animal models. We first found that dietary sphingolipids inhibit colon cancer and inflammatory bowel disease by regulating immune systems. I also found that SphK1 deficiency inhibits chemically-induced tongue (head & neck) cancer by mediating Akt phosphorylation. To determine whether inhibition of SphK1 induces cardiovascular side-effects, we employed chemically-induced hypertension mice models. We demonstrated that inhibition of SphK1 did not exacerbate hypertension in mice. Recently, we demonstrated that SphK1 deficiency decreased tumor development in HER2 transgene-induced breast cancer. Thus, SphK1 can be a potential preventive and therapeutic target without cardiovascular side effects.

Selected Publications

Shimizu Y, Furuya H, Bryant-Greenwood P, Chan O, Dai Y, Thornquist M, Goodison S, Rosser CJ. (2016). A multiplex immunoassay for the non-invasive detection of bladder cancer. J Transl Med, 14(1):31.

Burnier A, Shimizu Y, Dai Y, Nakashima M, Matsui Y, Ogawa O, Rosser CJ, Furuya H. (2015). CXCL1 is elevated in the urine of bladder cancer patients. Springerplus, 4:610,

Zhang G, Gomes-Giacoia E, Dai Y, Lawton A, Miyake M, Furuya H, Goodison S, Rosser CJ. (2014). Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. Diagn Pathol, 9:200.

Furuya H, Wada M, Shimizu Y, Yamada, PM, Hannun YA, Obeid LM, Kawamori T. (2013). Effect of sphingosine kinase 1 inhibition on blood pressure. FASEB J, 27: 656-664.

Furuya, H, Shimizu, Y., Kawamori, T. (2011). Sphingolipids in cancer. Cancer Metastasis Rev, 30: 567-76.

Shirai K, Kaneshiro T, Wada M, Furuya H, Bielawski J, Hannun YA, Obeid L, Ogretmen B, Kawamori T. (2011). A Role of Sphingosine Kinase 1 in Head & Neck Carcinogenesis. Cancer Prev Res (Phila), 4: 454-62.

Furuya H, Ohkawara S, Nagashima K, Asanuma N, Hino T. (2008). Dietary sphingomyelin alleviates experimental inflammatory bowel disease in mice. Int J Vitam Nutr Res, 78: 41-48.

Publication list via PubMed